REG - Kanabo Group PLC - Board Change

KanaboAnnouncement

04/05/2023 16:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230504:nRSD4820Ya&default-theme=true

RNS Number : 4820Y  Kanabo Group PLC  04 May 2023

4 May 2023

 

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

 

Board Change

 

Kanabo Group Plc (LSE: KNB), the patient focused healthcare technology and
medicinal cannabis company, announces the appointment of Sharon Malka as
Non-Executive Director ("NED") with immediate effect.

 

The Company also announces that Gil Efron will step down from his position as
a Non-Executive Director with immediate effect, in order to focus on his
rehabilitation following a recent accident. Sharon Malka will assume the role
of Chair of the Audit Committee following Gil's departure.

 

Sharon Malka brings a wealth of experience to Kanabo, having held senior
leadership positions with a number of international healthcare and technology
companies. Sharon Malka is currently Chief Executive Officer of Dotz Nano Ltd.
("Dotz"), an Australian-based technology company focused on developing,
manufacturing and commercialising advanced materials for diagnostics
solutions. In addition to his position at Dotz, Sharon Malka has spent the
past 16 years at MediWound Limited, a Nasdaq-listed biopharmaceutical company.
Sharon is a member of MediWound Limited's Board of Directors, and he has
previously been MediWound Limited's Chief Financial Officer and Chief
Executive Officer. Previously, Sharon held the role of Partner at Variance
Economic Consulting Ltd., a financial services consulting boutique focused on
international technology companies, and served as a Senior Manager position
for PwC Corporate Finance.

 

Sharon Malka is a qualified accountant and holds a B.Sc. in Business
Administration from the Business Management College in Israel and an M.B.A.
from Bar Ilan University, Israel.

 

David Tsur, Deputy Chair of Kanabo, commented:

 

"We would like to thank Gil for his significant contribution, dedication and
commitment to Kanabo and we hope he makes a full and speedy recovery.

 

"On behalf of the Board, I would like to welcome Sharon to Kanabo. He brings a
wealth of experience in innovative technology companies and capital markets.
We look forward to benefitting from his knowledge and expertise as we continue
to focus on expanding the service offering and market reach for Kanabo
services and products."

 

Save for the information disclosed below, Kanabo confirms there is no further
information to be disclosed under the requirements of Listing Rule 9.6.13 in
relation to the appointment of Sharon Malka as Non-Executive Director.

 

The information communicated in this announcement is inside information for
the purposes of Article 7 of Regulation 596/2014.

 

 

 Current Directorships            Non-current directorships (past 5 years)
 Dotz Nano Ltd.                   MediWound UK Limited

 MediWound Limited

 

Enquiries:

 

 Kanabo Group plc                                                  via Vigo Consulting

 Avihu Tamir, Chief Executive Officer                              +44 (0)20 7390 0230

 Assaf Vardimon, Chief Financial Officer

 Peterhouse Capital Ltd (Financial Adviser)                        +44 (0)20 7469 0930

 Eran Zucker

 Vigo Consulting (Financial Public Relations/Investor Relations)    +44 (0)20 7390 0230

 Jeremy Garcia / Fiona Hetherington / Verity Snow

 kanabo@vigoconsulting.com

 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a healthtech company committed to
revolutionising patient care through its innovative technology platform and
disruptive product offerings. Since its inception in 2017, Kanabo has been
focused on researching, developing, and commercialising regulated medicinal
cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides
patients with video consultations, online prescriptions, and primary care
services. The Company is a leader in its field, focusing on improving patient
outcomes and providing more accessible healthcare experiences.

 

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under
the expert guidance of its technological and product expertise. Treat It
initially focuses on chronic pain management using plant-based medicine and
treatments that are currently unavailable through traditional channels.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest
quality medical treatments and more accessible healthcare experiences.

Visit www.kanabogroup.com (http://www.kanabogroup.com) for more information.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPUAWAUPWGAC